You don't know what you are talking about and you are not medical doctor.
But these guys do. So there is
that.
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1. Crawford NW, Bines JE, Royle J, Buttery JP. Optimizing immunization in pediatric special risk groups.
Expert Rev. Vaccines. 2011;10(2):175–186. [
PubMed] [
Google Scholar]
2. Liu MA. Immunologic basis of vaccine vectors.
Immunity. 2010;33(4):504–515. [
PubMed] [
Google Scholar]
3. Hilleman MR. Recombinant vector vaccines in vaccinology.
Dev. Biol. Stand. 1994;82:3–20. [
PubMed] [
Google Scholar]
4. Deering RP, Kommareddy S, Ulmer JB, Brito LA, Geall AJ. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.
Expert Opin. Drug Deliv. 2014;11(6):885–899. [
PubMed] [
Google Scholar]
5. Pascolo S. Vaccination with messenger RNA (mRNA) In: Bauer PDS, Hartmann PDG, editors.
Toll-Like Receptors (TLRs) and Innate Immunity. Springer Berlin Heidelberg; Germany: 2008. pp. 221–235. [
Google Scholar]
6. Jäschke A, Helm M. RNA sex.
Chem. Biol. 2003;10(12):1148–1150. [
PubMed] [
Google Scholar]
7. Fotin-Mleczek M, Duchardt KM, Lorenz C, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
J. Immunother. 2011;34(1):1–15. [
PubMed] [
Google Scholar]
8. Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants.
Vaccine. 2011;29(17):3341–3355. [
PMC free article] [
PubMed] [
Google Scholar]
9. Sorrentino S. Human extracellular ribonucleases: multiplicity, molecular diversity and catalytic properties of the major RNase types.
Cell. Mol. Life Sci. CMLS. 1998;54(8):785–794. [
PubMed] [
Google Scholar]
10. Chira S, Jackson CS, Oprea I, et al. Progresses towards safe and efficient gene therapy vectors.
Oncotarget. 2015;6(31):30675–30703. [
PMC free article] [
PubMed] [
Google Scholar]
11. Ku SH, Jo SD, Lee YK, Kim K, Kim SH. Chemical and structural modifications of RNAi therapeutics.
Adv. Drug Deliv. Rev. 2015 Epub ahead of print. [
PubMed] [
Google Scholar]
12. Lundstrom K. Alphaviruses in gene therapy.
Viruses. 2009;1(1):13–25. [
PMC free article] [
PubMed] [
Google Scholar]
13. Ogris M, Brunner S, Schüller S, Kircheis R, Wagner E. PEGylated DNA/transferring–PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery.
Gene Ther. 1999;6(4):595–605. [
PubMed] [
Google Scholar]
14. Bessis N, GarciaCozar FJ, Boissier M-C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms.
Gene Ther. 2004;11(S1):S10–S17. [
PubMed] [
Google Scholar]
15. Baum C, Kustikova O, Modlich U, Li Z, Fehse B. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors.
Hum. Gene Ther. 2006;17(3):253–263. [
PubMed] [
Google Scholar]
16. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy.
Nat. Rev. Genet. 2007;8(8):573–587. [
PMC free article] [
PubMed] [
Google Scholar]
17. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy.
Nat. Rev. Genet. 2003;4(5):346–358. [
PubMed] [
Google Scholar]
mRNA vaccine delivery using lipid nanoparticles
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439223/